Testosterone Enanthate vs AndroGel: Titration Speed and Tolerability Compared

How Each Formulation Works Pharmacokinetically

Testosterone enanthate is an esterified prodrug injected intramuscularly or subcutaneously. After injection, it forms a depot in muscle tissue, releasing free testosterone as the ester is cleaved. The half-life is approximately 4.5 days, which means a single 200 mg injection produces a measurable peak at 24 to 72 hours, then declines steadily until the next dose [1].

AndroGel 1.62% is absorbed transdermally, bypassing first-pass hepatic metabolism. Applied once daily to shoulders or upper arms, it produces a relatively flat serum profile. According to the FDA-approved AndroGel 1.62% prescribing information, steady-state concentrations are reached within approximately two days of consistent application [2].

Why the Delivery Route Changes Everything

The injection route concentrates the dose into a single pharmacokinetic event per week or per two weeks. A man injecting 200 mg every 14 days may see a peak total testosterone of 900 to 1,100 ng/dL on day 2, falling to 350 to 450 ng/dL by day 13. That 500 to 650 ng/dL swing is pharmacologically real and clinically relevant, correlating with mood variability and libido fluctuation reported in observational data [3].

Transdermal delivery eliminates that spike-and-valley pattern. Daily application means the serum level on Monday morning is nearly identical to Thursday evening, assuming consistent application time and site rotation. The tradeoff is that absorption varies by 10 to 15% between individuals based on skin thickness, hydration, and follicular density, which prolongs the titration process [2].

Bioavailability Numbers That Actually Matter

Testosterone enanthate delivers close to 100% bioavailability by the intramuscular route. Subcutaneous injections show slightly lower peak levels but comparable area-under-the-curve in small pharmacokinetic studies [4]. AndroGel absorption is approximately 10% of the applied dose, meaning a 40.5 mg pump actuation delivers roughly 4 mg of absorbed testosterone. This low but predictable absorption fraction is why gel doses are calibrated in milligrams of gel, not milligrams of testosterone.

Titration Speed: Which Formulation Gets You to Target Faster

Testosterone enanthate reaches a rough pharmacokinetic steady state after two to three injection cycles, meaning most men can draw their first trough lab around week 2 to 4 and make a meaningful dose decision. AndroGel titration takes longer in practice, not because steady state is slow (it is reached in two days), but because the dose steps on the FDA label are large relative to the inter-individual absorption variance [2].

Enanthate Titration Protocol in Clinical Practice

A standard starting dose of 100 mg every 7 days or 200 mg every 14 days is drawn at trough (the morning of the next scheduled injection, before dosing). The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends targeting a mid-normal range trough of approximately 400 to 700 ng/dL [5]. If the trough is below 300 ng/dL, the dose is increased by 25 to 50 mg or the injection interval is shortened. Most men reach a stable, tolerable dose within 6 to 10 weeks.

AndroGel Titration Protocol in Clinical Practice

The FDA label for AndroGel 1.62% specifies a starting dose of two pump actuations (40.5 mg) per day, with a first lab check at day 14 and subsequent adjustments to one pump (20.25 mg) or four pumps (81 mg) based on the result [2]. Because absorption varies between patients, some men require two or three adjustment cycles, extending practical titration to 60 to 90 days before the prescriber is confident in the dose. Checking testosterone at the same time of day (typically two to four hours after application) is required for interpretable results [5].

Head-to-Head Titration Comparison Table

| Factor | Testosterone Enanthate | AndroGel 1.62% | |---|---|---| | Time to first meaningful lab | 2 to 4 weeks (trough) | 14 days post-start or post-change | | Typical dose-stable window | 6 to 10 weeks | 8 to 16 weeks | | Dose adjustment increment | 25 to 50 mg | 20.25 mg (1 pump) | | Number of adjustment steps needed | 1 to 2 on average | 1 to 3 on average | | Lab timing requirement | Morning of injection day | 2 to 4 hours post-application |

Tolerability: Side Effects and Which Patients Struggle With Each

Both formulations carry the same androgen-class adverse effects: erythrocytosis, acne, suppression of spermatogenesis, and potential worsening of sleep apnea [5]. The formulation-specific tolerability differences relate to the delivery mechanism itself.

Injection Site Reactions and Injection Anxiety

Testosterone enanthate in sesame or cottonseed oil is a viscous solution. Intramuscular injection into the gluteus medius or vastus lateralis may cause post-injection soreness lasting 24 to 72 hours, particularly at the 200 mg dose volume (typically 1 mL). Subcutaneous injection with a 27-gauge, 0.5-inch needle reduces pain considerably and is supported by pharmacokinetic data showing equivalent testosterone exposure [4]. Men with significant needle phobia frequently discontinue injectable TRT within the first three months, based on retention data from specialty TRT clinics [6].

Skin and Application Site Issues With Gel

Contact transfer is the most serious tolerability concern specific to gels. The FDA added a black-box warning to all topical testosterone products after case reports documented virilization in children who had skin contact with gel-treated adults [2]. Application site reactions (erythema, dryness, pruritus) occur in roughly 5% of users per prescribing data. Men with eczema, psoriasis, or highly variable skin hydration may absorb testosterone inconsistently, making stable titration difficult.

Polycythemia Risk by Formulation

Erythrocytosis (hematocrit above 54%) is more common with injectable testosterone than with transdermal formulations. A 2013 meta-analysis of 51 randomized trials (N = 3,016) published in JAMA Internal Medicine found that injectable testosterone raised hematocrit more than transdermal testosterone, with the injectable group showing a statistically significant increase in polycythemia risk (relative risk 3.67, 95% CI 1.82 to 7.51) [7]. Men who have had a prior thromboembolic event or have baseline hematocrit above 48% may therefore tolerate gel better from a hematologic standpoint.

Mood and Energy: The Peak-Trough Experience

Men injecting on a 14-day schedule frequently describe an energy and libido peak in days 2 to 5 followed by a gradual decline in the final three to four days before the next injection. This phenomenon is well-documented in patient-reported outcome data and correlates with the pharmacokinetic trough [3]. Shortening the injection interval to every 7 days, or switching to subcutaneous micro-dosing (50 mg twice weekly), substantially reduces this variability. Men who remain on a 14-day schedule and find the troughs intolerable are reasonable candidates to switch to daily transdermal gel.

The T-Trials: What the Landmark Evidence Actually Shows

The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016, remain the highest-quality evidence base for TRT in older men with documented low testosterone. The trial enrolled 788 men aged 65 or older with a serum testosterone below 275 ng/dL and used testosterone gel (AndroGel 1%) titrated to maintain levels between 500 and 1,000 ng/dL [8].

The T-Trials demonstrated statistically significant improvements in sexual function and mood, with modest effects on physical function. Bone mineral density improved significantly in the bone trial sub-study. Cardiovascular signal analysis from the T-Trials did not show a significant increase in adverse cardiac events over 12 months, though the study was not powered for cardiovascular outcomes [8].

Critically, the T-Trials used gel, not injections. Clinicians sometimes ask whether the results apply to enanthate. Because the trial was designed to achieve similar serum levels regardless of formulation, the physiologic effects at equivalent testosterone exposure are expected to be comparable. The titration methodology, however, was gel-specific: the research team adjusted doses monthly based on mid-cycle levels, not trough levels [8]. Translating that protocol to injection schedules requires a different lab-timing approach, as outlined by the Endocrine Society guideline [5].

Switching From Testosterone Enanthate to AndroGel

Switching is clinically reasonable for men who experience intolerable injection site discomfort, pronounced peak-trough mood cycling, or polycythemia that persists despite dose reduction. The switch requires a washout strategy because enanthate depots in subcutaneous tissue continue releasing testosterone for 10 to 14 days after the last injection.

Practical Switching Protocol

A safe transition starts the gel on the day the next injection would have been due, not the day after the last injection. Starting gel while the enanthate depot is still active risks supraphysiologic peaks and hematocrit elevation. The first lab check after switching should occur at day 14 to 21 of gel use, timed two to four hours after application. Expect the first trough check to show lower testosterone than the injection trough because gel delivers lower peak levels by design [2].

Men switching for polycythemia management may need a therapeutic phlebotomy before or shortly after the switch if hematocrit is above 52%, since the gel's lower peak profile takes 4 to 6 weeks to reduce erythropoietic drive.

Lab Targets During the Switch

The Endocrine Society guideline recommends a target serum testosterone of 400 to 700 ng/dL for trough measurements on injectables, and a mid-morning level of 400 to 700 ng/dL for transdermal formulations [5]. Do not compare a peak injection level to a gel level and conclude the gel is insufficient: the relevant comparison is trough-to-trough or midpoint-to-midpoint, not peak-to-midpoint.

According to the American Urological Association's 2018 guideline on testosterone deficiency, "testosterone therapy should be initiated at a dose designed to bring serum testosterone to the mid-normal range, with dose adjustments based on symptom response and serum levels checked at 3 to 6 months after initiation" [9]. That principle applies equally to both formulations.

Cost, Convenience, and Adherence

Cost Comparison

Generic testosterone enanthate is among the least expensive TRT options available. A 10 mL multi-dose vial (200 mg/mL) costs approximately $30 to $80 at most U.S. Pharmacies, providing 10 to 20 weekly doses. Brand-name AndroGel 1.62% without insurance can exceed $500 per month. Generic testosterone gel formulations (1%) are available for $50 to $120 per month at compounding pharmacies or through GoodRx-linked programs, substantially narrowing the cost gap [10].

Adherence Patterns

Daily application demands more consistent behavior than weekly or biweekly injections. A 2020 retrospective cohort study of 9,410 men initiating TRT found that 12-month adherence was 68% for injectable testosterone versus 54% for topical formulations, with the leading reason for gel discontinuation being application inconvenience and transfer concerns [6]. Men who travel frequently, live with young children, or share a bed with a partner who objects to gel residue tend to adhere better to injectables.

Injection Frequency Options That Change the Calculus

Comparing a 14-day injection schedule to a daily gel application is not the only relevant comparison. Men who self-inject subcutaneously twice per week (50 mg per dose) achieve serum stability that rivals daily gel while retaining cost and convenience advantages of injectables. This approach has become increasingly common in direct-to-patient TRT programs and is supported by pharmacokinetic modeling data showing Cmax/Ctrough ratios below 1.5 on twice-weekly subcutaneous dosing [4].

Absolute and Relative Contraindications Relevant to Formulation Choice

Both testosterone enanthate and AndroGel share the same class-level contraindications: known or suspected prostate cancer, breast cancer in men, and pregnancy (in female partners, due to exposure risk with gel) [2, 5]. Formulation-specific considerations include:

• Men with active skin conditions affecting the application area should avoid gel formulations until the condition is controlled.
• Men with young children at home require strict transfer-prevention protocols with gel (covering the application site, washing hands, showering before physical contact).
• Men with a documented sesame or cottonseed oil allergy should not use the standard oil-based enanthate formulations; aqueous suspension or alternative carriers may be available through compounding.
• Men with hematocrit at or above 50% at baseline should use gel rather than injectable formulations when possible, based on the differential polycythemia risk data [7].

The FDA prescribing information for AndroGel 1.62% states that testosterone products are contraindicated in men with "carcinoma of the breast or known or suspected carcinoma of the prostate" and that "patients with BPH treated with testosterone may be at increased risk for worsening of signs and symptoms of BPH" [2].

Monitoring Schedule by Formulation

Adequate monitoring is non-negotiable with either formulation. The Endocrine Society recommends checking serum testosterone, hematocrit, and PSA at 3 to 6 months after initiation, then annually if stable [5]. The following differences apply by formulation:

For testosterone enanthate: Draw blood in the morning on injection day (trough), before administering the dose. For a 7-day schedule, this is day 7. For a 14-day schedule, this is day 14. A single mid-cycle check (around day 3 to 4 for a 7-day schedule) can help characterize the peak if supraphysiologic symptoms are reported.

For AndroGel 1.62%: Draw blood 2 to 4 hours after application on a typical application day. Do not draw in the evening or before application, as this will underestimate the absorbed daily dose. The FDA label specifies this timing explicitly [2].

Hematocrit should be checked at 3 months, 6 months, and annually. If hematocrit exceeds 54%, testosterone should be dose-reduced or held, and the patient evaluated for sleep apnea as a contributing cause [5]. A PubMed-indexed review of TRT monitoring in primary care found that fewer than 40% of men on TRT receive guideline-concordant hematocrit monitoring, suggesting this is an underperformed step in routine practice [11].